CA-ODASEVA
12.9.2019 14:02:14 CEST | Business Wire | Press release
Odaseva , the unified cloud data protection, compliance and operations platform for enterprises running Salesforce as a business-critical application, today announced that it has seen triple year over year growth, and after only seven years of operation, supports a staggering one trillion Salesforce records, with over 10 million enterprise-level internal Salesforce customers.
Odaseva’s explosive growth is in part due to the influx of new data privacy and governance laws such as GDPR or CCPA , demanding that businesses put in place specific regulations such as Data Subject Rights (which stipulates that consumers have the right to access their own private information) and leverage more robust data governance solutions to shield and manage private customer information. Odaseva, which began in 2012 with one client, Schneider Electric, has rapidly increased its enterprise customer base including Toyota France, Robert Half International and GE, offering organizations the ability to augment their existing cloud data protection solutions.
“Comprehensive compliance automation and data protection are essential for organizations coping with increasingly complex and costly privacy regulations as varied as HIPAA, GDPR, CCPA and PIPEDA,” says Sovan Bin, founder and CEO of Odaseva. “As confidential personal data is often distributed across multiple clouds, as well as on-premises data centers, our goal at Odaseva has been to introduce consistency in how audit information is gathered and presented as well as preserved, in order to provide a measure of relief for businesses striving to comply with multiple regulations.
“No other technology vendor today can offer such a unified cloud data governance suite for Salesforce as Odaseva,” Sovan Bin continued.
Recent Investments and Increased Headcount
In 2019, Odaseva raised $11.7m in Series A funding round, which brought the total funding for Odaseva to $14 million. The round was led by Partech with participation from new investor Salesforce Ventures and existing investor Serena. These new investments have allowed Odaseva to direct a portion of the new funding to build on existing sales and technology partnerships with Accenture, Capgemini, CGI, and Deloitte.
In addition, Odaseva has doubled their headcount in the past six months with new hires including a new chief legal officer and a vice president of customer and partner success.
Located in San Francisco and Paris, Odaseva continues to actively recruit in both locations and is looking to expand its operations globally.
Added New Products to Portfolio Line-up:
The hallmark of Odaseva’s solution lies in its compliance automation tools such as GDPR for Salesforce which allows the enterprise to automate a broad range of data procedures from backup to archival, audit, and more in order to comply with industry regulations.
However in 2019 alone, Odaseva announced several new tools to complete their portfolio that have included the following:
- Cockpit AI: With advanced machine learning capabilities, Cockpit AI offers the first predictive capacity management system to help enterprise Salesforce users maximize the value of the platform by automating the process of monitoring and forecasting the use of platform allocations – such as file storage, data storage and API calls on Salesforce
- Vault: Works with the Odaseva platform to help users automatically archive sensitive data that organizations are required to keep for long periods of time in regulated industries such as financial services, healthcare and insurance. Not only will the information be kept safe from any unauthorized users, but Odaseva ensures a data durability level of 99.999999999% over a given year.
- Full Sandbox Anonymization application (FSA) for Salesforce customers . The application works with the Odaseva platform to anonymize all personal information that an organization may put in a Salesforce Full Sandbox – which is an isolated copy of an organization’s Salesforce environment that can be used for training, development and testing.
About Odaseva
For enterprises that leverage Salesforce as a mission-critical application, Odaseva delivers enterprise-class data governance, providing data protection (backup and recovery, archiving, governor limits monitoring), data compliance for regulation requirements such as GDPR and data operations (Salesforce DX data extensions). Odaseva was engineered for Salesforce by Salesforce experts and is endorsed by Salesforce Ventures. Over 10+Million Salesforce Enterprise users from industry-leading companies such as Schneider Electric, Heineken and Robert Half trust Odaseva’s data governance platform.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005206/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom